Trump’s generic drugs tariff threatens Indian pharma’s top market

100% levy from 2028 could accelerate push into higher value medicines The U.S. accounted for about 37% of India's nearly $26 billion in pharma exports in 2025, the Global Trade Research Initiative estimates. © Reuters BENGALURU — Washington's move to put a 100% tariff on generic drug imports threatens the access of India's pharmaceutical industry to its largest market while upping the pressure to expand into higher-value medicines, with shares of several drugmakers sliding on fears that shifting production to the U.S. would be a gargantuan task.

Read the full article at the source →